Kevin Leach - Axogen Vice President - Marketing
| AXGN Stock | USD 6.87 0.10 1.43% |
President
Mr. Kevin Leach is the Vice President Marketing of the AxoGen, Inc. Mr. Leach was AxoGens Vice President of Marketing since March 2016. Prior to joining AxoGen, Mr. Leach worked in a consulting capacity between September 2015 and March 2016 for startup companies supporting strategic planning and due diligence activities for targeted acquisitions. Mr. Leach previously served as Vice President of Marketing for Stryker within their orthopedic division, where he led the overall knee strategy from September 2013 through August 2015. From February 2013 to September 2013 Mr. Leach served as marketing consultant for SteadMed Medical, a medical device company focusing on acute and chronic wounds. From January 2008 to February 2013 Mr. Leach served in marketing roles with increasing responsibility including as Vice President, Marketing with ConvaTec, a medical products and technologies company with leading market positions in Wound Therapeutics, Ostomy Care, Continence and Infusion Devices. ConvaTec was acquired by private equity firms Nordic Capital and Avista Capital Partners in 2008. Prior to moving to the United States, from October 2000 to January 2008, Mr. Leach was a global marketing leader for ConvaTec, a BristolMyers Squibb company where he led the launch of new products globally. From February 1999 to October 2000 Mr. Leach served as Business Unit Manager at Zimmer UK, within a newly established division for the orthopedic business unit focusing on market development and commercialization of an injectable hyaluronic acid for the relief of joint pain. From January 1992 to February 1999 Mr. Leach held various sales and marketing roles within the UK division of ConvaTec. Mr. Leach qualified as a Podiatrist from Queen Margaret University in Edinburgh. since 2016.
| Age | 47 |
| Tenure | 8 years |
| Address | 13631 Progress Boulevard, Alachua, FL, United States, 32615 |
| Phone | 386 462 6800 |
| Web | https://www.axogeninc.com |
Axogen Management Efficiency
The company has return on total asset (ROA) of (0.0684) % which means that it has lost $0.0684 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2208) %, meaning that it created substantial loss on money invested by shareholders. Axogen's management efficiency ratios could be used to measure how well Axogen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to drop to -0.12. In addition to that, Return On Capital Employed is likely to grow to -0.12. At this time, Axogen's Debt To Assets are very stable compared to the past year. As of the 24th of April 2024, Asset Turnover is likely to grow to 0.95, though Non Currrent Assets Other are likely to grow to (83.2 M).Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.0684 |
Axogen Inc Leadership Team
Elected by the shareholders, the Axogen's board of directors comprises two types of representatives: Axogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axogen. The board's role is to monitor Axogen's management team and ensure that shareholders' interests are well served. Axogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Davault, VP Marketing | ||
| Mark Friedman, Vice President - Regulatory and Quality | ||
| John Engels, Co-Founder and VP | ||
| Jamie Grooms, Co-Founder, Chairman, Member of Audit Committee and Member of Governance and Nominating Committee | ||
| Shawn McCarrey, Sr. VP of Sales | ||
| Kevin Leach, Vice President - Marketing | ||
| Joseph Mandato, Independent Director | ||
| Mike Donovan, Director of Operations | ||
| CFA CPA, Chief Officer | ||
| Kaila Krum, Vice President Investor Relations and Corporate Development | ||
| Christopher Crisman, Vice President - U.S. Sales | ||
| Alan Levine, Director | ||
| Guido Neels, Director | ||
| Marc Began, General VP | ||
| Michael Donovan, Vice Operations | ||
| James Grooms, Independent Chairman of the Board | ||
| Doris Quackenbush, Vice Sales | ||
| Harold Tamayo, Vice Relations | ||
| Quentin Blackford, Director | ||
| Robert Rudelius, Independent Director | ||
| Angelo Scopelianos, Vice President - Research & Development | ||
| Peter Mariani, Ex CFO | ||
| Maria Martinez, Chief Human Resource Officer | ||
| Eric Sandberg, Chief Commercial Officer | ||
| Amy Wendell, Director | ||
| Erick DeVinney, Vice President of Clinical and Translational Sciences | ||
| Lisa Colleran, Director | ||
| Karen Zaderej, CEO and President and Director | ||
| Isabelle Billet, Chief Strategy and Business Development Officer | ||
| Jens Kemp, Chief Officer | ||
| Gregory Freitag, Senior Vice President - Business Development, General Counsel, Director | ||
| David Hansen, Corporate Controller | ||
| Bradley JD, G Officer | ||
| Ed Joyce, Director Relations | ||
| Jon Gingrich, Chief Commercial Officer | ||
| Mark Gold, Independent Director | ||
| Ivica MD, Chief Officer |
Axogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.0684 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 342.4 M | ||||
| Shares Outstanding | 43.69 M | ||||
| Shares Owned By Insiders | 5.05 % | ||||
| Shares Owned By Institutions | 77.24 % | ||||
| Number Of Shares Shorted | 1.73 M | ||||
| Price To Earning | (47.07) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Axogen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Axogen's short interest history, or implied volatility extrapolated from Axogen options trading.
Pair Trading with Axogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axogen will appreciate offsetting losses from the drop in the long position's value.Moving against Axogen Stock
| 0.71 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.64 | NXL | Nexalin Technology | PairCorr |
| 0.64 | AGTI | Agiliti Financial Report 14th of May 2024 | PairCorr |
| 0.61 | ELEV | Elevation Oncology Earnings Call Next Week | PairCorr |
| 0.46 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
The ability to find closely correlated positions to Axogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axogen Inc to buy it.
The correlation of Axogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Axogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Axogen Inc information on this page should be used as a complementary analysis to other Axogen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Axogen Stock analysis
When running Axogen's price analysis, check to measure Axogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axogen is operating at the current time. Most of Axogen's value examination focuses on studying past and present price action to predict the probability of Axogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axogen's price. Additionally, you may evaluate how the addition of Axogen to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Axogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axogen. If investors know Axogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Revenue Per Share 3.708 | Quarterly Revenue Growth 0.187 | Return On Assets (0.07) | Return On Equity (0.22) |
The market value of Axogen Inc is measured differently than its book value, which is the value of Axogen that is recorded on the company's balance sheet. Investors also form their own opinion of Axogen's value that differs from its market value or its book value, called intrinsic value, which is Axogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axogen's market value can be influenced by many factors that don't directly affect Axogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Axogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.